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Summary

Background The SARS-CoV-2 pandemic is a worldwide challenge. The CRIT-CoV-U pilot study generated a urinary
proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from
SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full
dataset to consolidate the findings and propose potential clinical applications of this biomarker.
Methods CRIT-CoV-U was a prospective multicentre cohort study. In eight European countries (Austria, France,
Germany, Greece, North Macedonia, Poland, Spain, and Sweden), 1012 adults with PCR-confirmed COVID-19 were
followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass
spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression and receiver
operating characteristic curve analysis with a comparison of the area under curve (AUC) between nested models.
Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching
WHO scores ranging from 3 to 8 and flat-rate hospitalisation costs adjusted for the gross per capita domestic product
of each country.
Findings From June 30 to Nov 19, 2020, 228 participants were recruited, and from April 30, 2020, to April 14, 2021,
784 participants were recruited, resulting in a total of 1012 participants. The entry WHO scores were 1–3 in 445 (44%)
participants, 4–5 in 529 (52%) participants, and 6 in 38 (4%) participants; and of all participants, 119 died and 271 had
disease progression. The odds ratio (OR) associated with COV50 in all 1012 participants for death was 2·44 (95% CI
2·05–2·92) unadjusted and 1·67 (1·34–2·07) when adjusted for sex, age, BMI, comorbidities, and baseline WHO
score; and for disease progression, the OR was 1·79 (1·60–2·01) when unadjusted and 1·63 (1·41–1·91) when
adjusted (p<0·0001 for all). The predictive accuracy of the optimised COV50 thresholds was 74·4% (71·6–77·1%) for
mortality (threshold 0·47) and 67·4% (64·4–70·3%) for disease progression (threshold 0·04). When adjusted for
covariables and the baseline WHO score, these thresholds improved AUCs from 0·835 to 0·853 (p=0·033) for death
and from 0·697 to 0·730 (p=0·0008) for progression. Of 196 participants who received ambulatory care, 194 (99%)
did not reach the 0·04 threshold. The cost reductions associated with 1 day less hospitalisation per 1000 participants
were million Euro (M€) 0·887 (5–95% percentile interval 0·730–1·039) in participants at a low risk (COV50 <0·04)
and M€2·098 (1·839-2·365) in participants at a high risk (COV50 ≥0·04).
Interpretation The urinary proteomic COV50 marker might be predictive of adverse COVID-19 outcomes. Even in
people with mild-to-moderate PCR-confirmed infections (WHO scores 1–4), the 0·04 COV50 threshold justifies
earlier drug treatment, thereby potentially reducing the number of days in hospital and associated costs.
Funding German Federal Ministry of Health.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license.

Introduction
The SARS-CoV-2 pandemic is a challenge for health care
worldwide. Globally, from Nov 15 to 21, 2021, nearly
3·6 million new cases and more than 51 000 deaths were
reported, reflecting continual increases in both metrics
compared with the preceding weeks.1 Despite the roll-out
www.thelancet.com/digital-health Vol 4 October 2022

of vaccines, the pandemic continues to burden health
care, given the emergence in 2022 of the omicron variant,
which has higher transmissibility and potentially more
resistance against immunological responses to vaccines
or a previous infection than previous variants.2,3 Patients
with COVID-19 who are admitted to hospital are usually
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Research in context
Evidence before this study
The literature and guidelines were reviewed with the objective
of assessing the efficacy of interventions in people with
COVID-19 relative to the disease stage at presentation.
We searched PubMed from Jan 1, 2020, to Dec 31, 2021, using
the terms: (COVID-19 OR SARS-CoV-2) AND (clinical trials OR
randomised trials OR randomized trials OR RCTs), which
identified 52 articles published in English in 2020 and 2021, and
which were all read and summarised. 11 studies enrolled
patients into ambulatory care with mild-to-moderate disease,
whereas all other studies recruited patients admitted to hospital
with moderate-to-severe disease. The median number of days
from symptom onset to intervention varied from 1 to 13 days.
Corticosteroids, antiviral drugs, anti-inflammatory drugs,
antiviral monoclonal antibodies, and fluvoxamine reduced the
viral load and disease progression, whereas all other tested drugs
and convalescent plasma did not modify the disease course.
All studies applied clinical criteria, risk factors, comorbidities, or
disease-severity scales to stratify for risk. No study implemented
a predictive biomarker to triage patients for ambulatory versus
hospital care or to assess the need for early intervention. Among
the directives for the management of people with COVID-19,
only the Arbeitsgemeinschaft der Wissenschaftlichen
Medizinischen Fachgesellschaften Leitlinie guidelines
mentioned the use of COV50, a urinary proteomic profile
biomarker.
Added value of this study
This study is the first to include a COVID-19-specific biomarker
to guide early intervention. COV50 consists of 50 differentially
regulated urinary peptides and is able to predict death and

stratified for risk on the basis of age, obesity, other
comorbidities, and several disease severity scales.4
Patients with COVID-19 have a prothrombotic or
thrombophilic state, with elevations of several biomark
ers reflecting thrombosis, fibrinolysis, and inflam
mation, which are associated with disease severity and
prognosis.5 However, none of these biomarkers are
specific for COVID-19 and most have not had
a prospective validation of the action threshold that
defines the need for intervention.5 In contrast, urinary
proteomic profiling (UPP) generates classifiers that are
representative of pathogenic molecular mechanisms,
which in the case of SARS-CoV-2 infection are generally
independent of the virus strain and might inform
treatment, in particular with pharmacological agents not
specifically directed against the variable S-protein
domains of mutated SARS-CoV-2 variants. After a request
from the German Government, an interim analysis of
the CRIT-CoV-U study described the discovery,
replication, and internal and external validation of
COV50.6 This novel UPP biomarker consists of
50 dysregulated urinary peptides (appendix pp 8–10) and

disease progression in adults with mild-to-moderate PCRconfirmed COVID-19 infection. The predictive accuracy of the
optimised COV50 thresholds was 74·4% for mortality and
67·4% for disease progression. When adjusted for covariables
and then the baseline WHO score, the continuously distributed
urinary marker and its optimised thresholds improved the area
under the curves from 0·835 to 0·854 to 0·853 for death and
from 0·697 to 0·740 to 0·730 for disease progression. Using the
0·04 threshold to differentiate low COVID-19-associated risk
from high COVID-19-associated risk would allow selecting
patients with mild disease at presentation for earlier drug
treatment, thereby decreasing the risk of worsening disease and
death and reducing hospitalisation costs.
Implications of all the available evidence
The crucial question emerging from the COVID-19 pandemic,
and from the omicron variant's becoming dominant with
high transmissibility, is how to prevent deterioration to
critical illness in people who are infected. A COV50 score of
0·04 or higher predicts disease progression in addition to
clinical criteria. Even in patients with mild-to-moderate
disease (WHO stages 1–4), a high-risk COV50 score is an
indication for early in-hospital treatment, thereby valorising
the results of the 2020–21 trials and reducing the burden on
health care. COV50 testing can also be applied for the
selection of patients in randomised clinical trials of innovative
COVID-19 treatment methods, in which risk at presentation is
an issue in the choice between ambulatory versus
hospitalised care or in the treatment method to be tested.
COV50 is registered in Germany and available for clinical use
in the EU.

predicts death and progression across the COVID-19
WHO stages beyond risk factors and comorbidities.6 The
objectives of the current study were to consolidate the
interim findings in the full CRIT-CoV-U study sample
and to propose the potential applications of the COV50
marker in clinical practice and trial design.

Methods

Study design and participants
The CRIT-CoV-U project complied with the Helsinki
declaration. The Ethics Committee of the GermanSaxonian Board of Physicians (Dresden, Germany;
number EKBR88/20·1) and the Institutional Review
Boards of the recruiting sites provided ethical approval.
The protocol was deposited at the German Register for
Clinical Studies (number DRKS00022495), which is
linked to the WHO International Clinical Trial Registry
Platform. The English version of the protocol is available
for download from: https://crit-cov.de/files/Crit-Cov/
Crit-Cov-U-study-protocol.pdf.
CRIT-CoV-U was a prospective multicentre cohort
study.6 Eligible participants were non-anuric adults
www.thelancet.com/digital-health Vol 4 October 2022
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(≥18 years), capable of giving written informed consent,
with PCR-confirmed SARS-CoV-2 infection diagnosed
in ambulatory care or on the first day of admission to
hospital. All participants meeting the eligibility criteria
were enrolled without any exclusion in two phases:
228 participants were recruited from June 30 to
Nov 19, 2020, and were included in the interim report;6
the recruitment of a further 784 participants was done
from April 30, 2020, to April 14, 2021, so that the full
study cohort comprised 1012 individuals. Five hospitals
participated in the initial enrolment of participants and
an additional 12 in the continued recruitment. Two sites
were located in Innsbruck and Vienna, Austria
(65 participants enrolled), one in Paris, France
(49 participants), seven in Bayreuth, Berlin, Düsseldorf,
Hamburg, Leipzig, München, and Stuttgart, Germany
(458
participants),
one
in
Athens,
Greece
(30 participants), one in Skopje, North Macedonia
(137 participants), four in Gdańsk, Katowice, Kraków,
and Wrocław, Poland (149 participants), one in Sevilla,
Spain (23 participants), and two in Skövde and Umea,
Sweden (101 participants).

Procedures
All participants were followed up until recovery,
hospital discharge, or death. On days 0–3, 4–7, and
10–21 after diagnosis, participants who were alive were
staged according to the 8-point WHO Clinical
Progression Scale.7 Electronic case report forms
(MARVIN EDC; XClinical, Munich, Germany) were
used for data compilation. For UPP, 10-mL urine
samples were collected in borated test tubes
(ExactoBac-U; Sarstedt, Nümbrecht, Germany) and
kept at –20°C or less until assayed. The methods for
capillary electrophoresis coupled with mass spectrom
etry, for peptide sequencing, and for the evaluation,
calibration, and quality control of the mass
spectrometric data are described in detail in the
appendix (pp 2–5). For identification of the urinary
biomarker, 196 urine samples were randomly selected
from those available from participants at days 4–7 and
days 10–21 after diagnosis, excluding participants at
WHO stages 4–5, allowing for a comparison of the UPP
profiles at WHO stages 1–3 (n=116) and 6–8 (n=80).6
The disease-specific classifier was developed by support
vector machine modelling and cross-validated by a takeone-out procedure with significance adjusted for the
false-discovery rate set at 0·05.6 The derivation cohort
included 228 participants, and the validation cohort
included 99 participants (appendix p 11). Finally, to
investigate the applicability of the COV50 biomarker,
from Feb 7 to March 16, 2022, a further
62 participants consecutively admitted to hospital with
PCR-confirmed COVID-19 infection without exclusion
were enrolled at the Department of Infectious Diseases
and Tropical Medicine at the Nephrology and
Kuratorium für Dialyse und Nierentransplantation
www.thelancet.com/digital-health Vol 4 October 2022

Renal Unit and Rheumatology at St Georg Hospital
(Leipzig, Germany) and followed up until death
or discharge. These 62 participants underwent the
same measurements and were statistically analysed by
the same methods as in the main study. SARS-CoV-2
variants were established using next-generation
sequencing of the whole genome of SARS-CoV-2
strains.

Statistical analysis and outcomes
The initial sample size calculations, informed by a proofof-concept study,8 required 212 participants with lifethreatening COVID-19 (WHO stage ≥6) to be compared
with 271 participants with mild symptoms (WHO
stage <4) to identify and validate a UPP biomarker with
75% sensitivity and 80% specificity. Given the 33%
progression rate from mild to severe disease in the pilot
study,8 and accounting for a 15% rate of missing data,
the sample size for the full study was initially set at
645 participants. On the basis of the interim study,6 in
which the mortality rate was 10% (23/228), the sample
size for the full study was revised to 1000 participants.
For database management and statistical analysis,
SAS software (version 9·4) was used. Significance was
a two-tailed p value of 0·05 or less. Means were compared
using the large-sample z test or ANOVA, and proportions
were compared using Fisher’s exact test. The predefined
endpoints were mortality and progression measured
using the 8-point WHO scale of disease
severity.6 The 95% CIs of rates were computed as
R ± 1·96 × √ (R × [100 – R] /T), where R is the rate and T is
the number of participants at risk of developing an adverse
outcome. The risk of incident endpoints was derived from
the baseline COV50 score by logistic regression,
unadjusted or adjusted for sex, age, the entry WHO scale,
and comorbidities including hypertension, heart failure,
diabetes, and cancer. These covariables were selected
because they were in line with known clinical risk factors
for COVID-19-related mortality,9 and because they had
also been applied in the interim report,6 thereby
maintaining consistency. In participants admitted to
hospital, serum creatinine was measured, allowing the
calculation of the glomerular filtration rate using the
formula published by the Chronic Kidney Disease
Epidemiology Collaboration,10 and further adjustment of
the logistic models for the estimated glomerular filtration
rate was done. Correlations between categorical variables
were computed using Fisher’s z transformation. The
differences in the COV50 odds ratios (ORs) between
initial and continued recruitment were tested by
introduction of the interaction between the study phase
and baseline COV50 in the logistic models. Performance
of COV50 in risk stratification was assessed by the area
under the receiver operating characteristic curve
(AUC-ROC) and the Delong approach to compare the area
under the curves (AUCs) between nested models. The
COV50 thresholds optimised by the Youden index

Medicine, München Klinik
Schwabing, München,
Germany (M Seilmaier MD);
Nephrology and Dialysis,
Internal Medicine III, Medical
University of Vienna, Vienna,
Austria (B Rumpf MD);
Department of Nephrology
and Transplantation Medicine,
Wrocław Medical University,
Wrocław, Poland
(Prof M Banasik PhD,
Prof M Krajewska MD);
Department of Nephrology,
Angiology and Rheumatology,
Hospital Bayreuth, Bayreuth,
Germany (L Catanese MD,
Prof H D Rupprecht MD);
University of Silesia, Katowice,
Poland (B Czerwieńska MD);
Department of Nephrology,
Skaraborg Hospital, Skövde
and Department of Molecular
and Clinical Medicine, Institute
of Medicine, The Sahlgrenska
Academy at the University of
Gothenburg, Gothenburg,
Sweden (B Peters MD); Research
and Development Centre,
Skaraborg Hospital, Skövde,
Sweden (B Peters MD,
Å Nilsson MSc); Department of
Gastroenterology, Hepatology
and Endocrinology, Robert
Bosch Hospital, Stuttgart,
Germany (K Rothfuss MD);
Division of Infectious Diseases
and Tropical Medicine, Leipzig
University Medical Centre,
Leipzig, Germany
(Prof C Lübbert); Institute of
Cardiovascular and Medical
Sciences, Glasgow, UK
(Prof H Mischak); MartinLuther-University HalleWittenberg, Halle an der Saale,
Halle, Germany (Prof J Beige)
Correspondence to:
Prof Joachim Beige, Department
of Infectious Diseases and
Tropical Medicine, Nephrology
and Kuratorium für Dialyse und
Nierentransplantation Renal Unit
and Rheumatology, Leipzig
DE-04129, Germany
joachim.beige@kfh.de
See Online for appendix
For the German Register for
Clinical Studies see www.drks.de
For the WHO International
Clinical Trial Registry Platform
see www.who.int/clinical-trialsregistry-platform

e729

Articles

Recruitment phase cohort
Initial
(N=228)

Full cohort
(N=1012)

Continued
(N=784)

p value

<0·0001

WHO score
1–3

90 (39%)

355 (45%)

4–5

107 (47%)

422 (54%)

··

529 (52%)

31 (14%)

7 (1%)

··

38 (4%)

6
COV50 score

–0·19 (1·52)

–0·24 (1·36)

0·59

445 (44%)

–0·23 (1·40)

Ethnicity
White ethnicity
All other ethnicities*

205 (90%)

685 (87%)

23 (10%)

99 (13%)

0·30

890 (88%)

..

122 (12%)

Sex
Women

94 (41%)

353 (45%)

0·31

447 (44%)

134 (59%)

431 (55%)

..

565 (56%)

Hypertension

137 (60%)

420 (54%)

0·082

557 (55%)

Heart failure

30 (13%)

124 (16%)

0·33

154 (15%)

BMI ≥30 kg/m²

59 (26%)

192 (24%)

0·67

251 (25%)

Diabetes

65 (28%)

192 (24%)

0·22

257 (25%)

Men

Cancer
Use of RAS blockers
Age
Systolic blood pressure (mm Hg)

13 (6%)

93 (12%)

0·012

106 (11%)

122 (54%)

305 (39%)

<0·0001

427 (42%)

63·1 (17·1)

62·1 (18·0)

0·46

62·3 (17·8)

129·8 (23·2)

127·7 (19·0)

0·16

128·2 (20·1)

Diastolic blood pressure (mm Hg)

75·9 (13·5)

76·2 (11·7)

0·74

76·2 (12·2)

Heart rate (beats per min)

83·4 (15·1)

81·9 (15·6)

0·21

82·2 (15·5)

BMI (kg/m²)

28·0 (5·4)

27·5 (5·2)

0·23

27·6 (5·2)

Glomerular filtration rate (mL per
min per 1·73 m²)†

93·4 (51·0)

83·2 (32·1)

0·0095

85·6 (37·6)

Data presented as n (%) or mean (SD). COV50 score is the ratio of the actual value to the standard run against each
sample. RAS blockers indicate blocker of the renin-angiotensin system, including angiotensin-converting enzyme
inhibitors and angiotensin-receptor blockers. Systolic and diastolic blood pressure and heart rate were missing in two
initially recruited participants and 29 participants recruited later. The p value refers to the differences in the patients’
characteristics between initial recruitment (June 30 to Nov 19, 2020) and continued recruitment (April 30, 2020, to
April 14, 2021). RAS=renin-angiotensin system. *All other ethnicites include Asian ethnicity (9 [1%]), Black ethnicity
(14 [1%]), and not recorded (99 [10%]). †Glomerular filtration rate estimated from serum creatinine using the Chronic
Kidney Disease Epidemiology Collaboration formula was measured in 191 patients admitted to hospital in the initial
phase, 625 patients in the continued recruitment phase, and 816 patients overall.

Table 1: Baseline characteristics

were 0·47 for mortality and 0·04 for worsening WHO
score.6 To evaluate the usefulness of the optimised COV50
thresholds in clinical decision making, multivariable
logistic models were run, adjusted for sex, age categorised
in tertiles (<55·0, 55·0–74·9, and ≥75·0 years), the entry
WHO score, the presence versus absence of obesity
(BMI ≥30 kg/m²), and comorbidities (hypertension, heart
failure, diabetes, and cancer). From these models, in
which participants with an entry WHO score of 6 were
excluded, each patient’s probability of an endpoint was
exported and compared with the reference category by
computing least square means in generalised linear
models. In this analysis the lowest level of each categorised
risk factor was used as reference.
Using SAS interactive matrix language (version 9.4), a
Markov chain simulation11 was bootstrapped 1000 times
to generate the transition probabilities from the entry
WHO score to the maximum WHO score during
e730

follow-up (appendix p 16). Transition probabilities were
computed for the whole cohort and for various risk
strata, which were defined by the entry COV50 score and
age (<65 vs ≥65 years). The transition probabilities
allowed extrapolating the number of participants
reaching follow-up WHO scores of 3–4, 5, and 6–8, and
therefore requiring regular (score 3–4), intermediate
(score 5), or intensive (score 6–8) care. Point estimates
and uncertainty limits were derived from the median
and from the 5th to the 95th percentile interval of the
bootstrapped distributions. Next, the expected
hospitalisation costs were computed in three steps. First,
the daily hospitalisation costs were adjusted for the gross
per capita domestic product of each country12 averaged
over 10 years (2011–21) using as a benchmark the
diagnosis-related per-day hospitalisation costs applicable
in Germany in 2021: €540 for regular care, €1590 for
intermediate care, and €1770 for intensive care. Next, the
derived hospitalisation costs, the observed number of
days in hospital, and the simulated number of
participants allowed for the computation of the point
estimates and uncertainty intervals of the expected costs.
Finally, the cost estimates for the whole cohort and the
risk strata were expressed in million Euro (M€) per 1000
participants hospitalised for 1 week. Hospitalisation
costs were balanced against the cost of the COV50 test
(€850 per test).

Role of the funding source
The funder of the study had no role in the study design,
data collection, data analysis, data interpretation, or the
writing of the report.

Results
From June 30 to Nov 19, 2020, 228 participants were
recruited, and from April 30, 2020, to April 14, 2021,
784 participants were recruited. The 1012 participants
making up the full dataset were on average aged
62·3 years, included 447 (44%) women, 557 (55%)
participants with hypertension, 154 (15%) with heart
failure, 257 (25%) with diabetes, and 106 (11%)
participants with cancer (appendix p 22). The WHO
score at enrolment (table 1) was 1–3 in 445 (44%)
participants, 4–5 in 529 (52%) participants, and 6 in
38 (4%) participants. The mean (IQR) COV50 score at
baseline was –0·23 (–1·27 to 0·80; appendix p 23).
Compared with the initially enrolled participants, those
recruited later scored lower on the WHO scale (table 1;
p<0·0001), included more participants with a history of
cancer (6% with the initial phase vs 12% with the
continued phase; p=0·012), but fewer participants on
inhibitors of the renin-angiotensin system (54% with the
initial phase vs 39% with the continued phase; p<0·0001).
Otherwise, participants recruited initially and later had
similar characteristics (table 1), particularly a similar
entry COV50 score (–0·19 vs –0·24; p=0·59). In the
whole study population (appendix p 12), the proportion
www.thelancet.com/digital-health Vol 4 October 2022
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Initial phase cohort
OR (95% CI)

p value

Continued phase cohort

Full cohort

OR (95% CI)

OR (95% CI)

p value

p value

Mortality
Number of deaths/number at risk (%)

25/228 (11%)

··

94/784 (12%)

··

119/1012 (12%)

··

Unadjusted

2·45 (1·69–3·54)

<0·0001

2·47 (2·02–3·03)

<0·0001

2·44 (2·05–2·92)

<0·0001

Adjusted for sex and age

2·30 (1·57–3·37)

<0·0001

1·88 (1·50–2·35)

<0·0001

2·04 (1·68–2·47)

<0·0001

Adjusted for sex, age, and baseline WHO score

2·18 (1·30–3·64)

0·0030

1·54 (1·21–1·96)

0·0005

1·65 (1·34–2·05)

<0·0001

Adjusted for sex, age, BMI, comorbidities, and
baseline WHO score

2·27 (1·34–3·83)

0·0023

1·55 (1·21–1·98)

0·0005

1·67 (1·34–2·07)

<0·0001

Progressing WHO score
Number of endpoints or events/number at
risk (%)

50/228 (22%)

··

221/784 (28%)

··

271/1012 (27%)

··

Unadjusted

1·95 (1·52–2·51)

<0·0001

1·77 (1·56–2·02)

<0·0001

1·79 (1·60–2·01)

<0·0001

Adjusted for sex and age

1·81 (1·38–2·35)

<0·0001

1·50 (1·29–1·73)

<0·0001

1·56 (1·38–1·77)

<0·0001

Adjusted for sex, age, and baseline WHO score

2·32 (1·56–3·46)

<0·0001

1·52 (1·29–1·79)

<0·0001

1·65 (1·42–1·92)

<0·0001

Adjusted for sex, age, BMI, comorbidities, and
baseline WHO score

2·32 (1·55–3·48)

<0·0001

1·51 (1·27–1·78)

<0·0001

1·63 (1·41–1·91)

<0·0001

Odds ratios given with 95% CIs express the risk for 1SD increment increases in COV50 score. Initial recruitment lasted from June 30, to Nov 19, 2020, and continued
recruitment from April 30, 2020, to April 14, 2021. Comorbidities include hypertension, heart failure, diabetes, and cancer. OR=odds ratio.

Table 2: Odds ratios relating outcome to COV50 by recruitment phase

of women and the mean values of diastolic blood
pressure decreased across the four increasing quartiles
of COV50 score distribution at baseline, whereas age,
heart rate, and the rates of hypertension, heart failure,
diabetes, and cancer increased. Among 816 participants
admitted to hospi
tal, the glomerular filtration rate
averaged 85·6 (SD 37·6) mL per min per 1·73 m²
(table 1), but the glomerular filtration rate was not
measured in 186 ambulatory participants.
No patient was lost to follow-up. Median follow-up was
10 days (5th to 95th percentile interval, 1–34) for mortality
(number of deaths, 119) and 10 days (2–26) for worsening
WHO score (number of participants with endpoint, 271).
In all 1012 participants, the correlation coefficient of the
baseline COV50 score with the baseline WHO score
were 0·663 (95% CI 0·627–0·696) and with the maximal
WHO score during follow-up were 0·663 (0·627–0·697);
and when adjusted for the glomerular filtration rate in
816 participants admitted to hospital, these estimates
were 0·442 (0·403–0·482) with the baseline WHO score
and 0·458 (0·378–0·539) with the maximal WHO score
during follow-up. The baseline COV50 distribution
shifted upward significantly when plotted against the
highest WHO score attained during follow-up (p<0·0001;
appendix p 24). In the whole study population (table 2),
the relative risk of death expressed per 1-SD increment in
COV50 score at baseline was 2·44 (95% CI 2·05–2·92)
unadjusted and 1·67 (1·34–2·07) when fully adjusted for
sex, age, BMI, the presence of comorbidities, and the
baseline WHO score; for progression in the WHO score
(p<0·0001; table 2), the corresponding ORs were 1·79
(1·60–2·01) unadjusted and 1·63 (1·41–1·91) when fully
adjusted. In analyses dichotomised by study phase, the
risk associated with COV50 was similar for both
www.thelancet.com/digital-health Vol 4 October 2022

endpoints, irrespective of adjustment (table 2). The
unadjusted ORs for mortality were 2·45 (1·69–3·54) for
the initial recruitment group versus 2·47 (2·02–3·03) for
the continued recruitment group (interaction
p value 0·96) and for worsening WHO score, 1·95
(1·52–2·51) for the initial recruitment group versus 1·77
(1·56–2·02) for the continued recruitment group
(interaction p value 0·52). The fully adjusted estimates
(table 2) for mortality were 2·27 (1·34–3·83) for the
initial recruitment group versus 1·55 (1·21–1·98) for the
continued recruitment group (interaction p value 0·94);
and for worsening WHO score, 2·32 (1·55–3·48) for the
initial recruitment group versus 1·51 (1·27–1·78) for the
continued recruitment group (interaction p value 0·16).
In unadjusted analyses of the whole study population,
the AUC of the continuously distributed COV50 urinary
marker was 0·81 (95% CI 0·77–0·85) for mortality and
0·72 (0·68–0·75) for worsening WHO score (appendix
p 13). In the whole study population, the incidence
proportion of mortality among participants with a
COV50 score less than the optimised threshold (0·47)
was 30 (4·32%; 95% CI 2·81–5·84%) of 694 versus 89
(28·0%; 23·1–33·0%) of 318 with a COV50 score equal to
or higher than the optimised threshold (p<0·0001); the
corresponding incidence proportions of a worsening
WHO score, analysed using an optimised threshold of
0·04, were 88 (15·0%; 12·1–17·9%) of 587 for a COV50
score less than the optimised threshold versus 183
(43·1%; 38·4–47·8%) of 425 for a COV50 score equal to
or higher than the optimised threshold (p<0·0001). The
optimised 0·47 threshold for mortality resulted in 74·8%
(66·0–82·3%) sensitivity, 74·4% (71·4–77·2%) specificity,
and 74·4% (71·6–77·1%) accuracy; for worsening WHO
score, the optimised 0·04 threshold generated 67·5%
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A

B

Mortality
(n=119/1012)
AUC (95%CI)

p value

Base model

0·785 (0·749–0·822)

+ Baseline WHO score

0·835 (0·803–0·867)

0·0001

+ Baseline WHO score + COV50

0·695 (0·659–0·730)

+ Baseline WHO score

0·697 (0·662–0·732)
0·740 (0·707–0·773)
0·730 (0·696–0·764)

Distribution
Threshold, 0·04

0·55
0·0001
0·0008

D
1·00

0·75

0·75
Sensitivity

1·00

0·50
Base model
Base model + baseline WHO score
Base model + baseline WHO score
+ COV50 distribution

0·25

0·50

0·25

0

0

E

F
1·00

1·00

0·75

0·75
Sensitivity

Sensitivity

p value

Base model

0·022
0·033

C

Sensitivity

AUC (95%CI)

+ Baseline WHO score + COV50

0·854 (0·826–0·883)
0·853 (0·824–0·883)

Distribution
Threshold, 0·47

Worsening WHO score
(n=271/1012)

0·50

0·25

0

0·50

0·25

0

0·25

0·50
1 - Specificity

0·75

1·00

0

0

0·25

0·50

0·75

1·00

1 - Specificity

Figure: COV50 performance adjusted for baseline risk factors in the full dataset for mortality and worsening
WHO score
Figure shows the sensitivity and specificity of the urinary marker COV50 for mortality versus survival (panels A–C)
and for progression versus non-progression in the baseline WHO score (panels D–F) during follow-up. The base
model included sex, age, BMI, and the presence of comorbidities (hypertension, heart failure, diabetes, or cancer).
In subsequent steps, the baseline WHO score was added and then COV50 score as a continuously distributed
variable (panels B and E) or as a categorised variable based on an optimised threshold of 0·47 for mortality
(panel C) or 0·04 for a worsening WHO score (panel F). At each step, the p values are for the comparison with the
preceding model. AUC=area under the curve.

(61·6–73·1) sensitivity, 67·3% (63·8–70·7%) specificity,
and 67·4% (64·4–70·3%) accuracy (appendix p 13). For
both endpoints, these estimates were consistent in the
early and continued recruitment phases (appendix p 13).
The ORs and discriminatory performance of single risk
factors are summarised by recruitment phase in the
appendix (p 14). In the whole study population, when
adjusted for sex, age, BMI, comorbidities, and the baseline
WHO score, COV50 analysed as a continuously distribut
ed variable and categorised per threshold significantly
improved the AUC (figure). For mortality, accounting for
the continuously distributed COV50 marker resulted in
an increase of the AUC from 0·835 (95% CI 0·803–0·867)
to 0·854 (0·826–0·883; p=0·022) and for the 0·47 COV50
e732

threshold, to 0·853 (0·824–0·883; p=0·033). For
worsening WHO score, the AUC increased from 0·697
(0·662–0·732) to 0·740 (0·707–0·773; p=0·0001) for the
continuously distributed marker and to 0·730
(0·696–0·764; p=0·0008) for the 0·04 threshold. Add
itional adjustment for the glomerular filtration rate in
816 participants admitted to hospital produced confirm
atory results (appendix pp 14, 25). In multivariable logistic
models from which participants with an entry WHO score
of 6 were excluded (table 3), the probability of death
increased 3·6 times (p<0·0001) from 6·2% (95% CI
5·8–6·6%) to 22·3% (21·7–23·0%) if the 0·47 threshold
was reached. Furthermore, the probability of progression
of the WHO score increased 2·97 times (p<0·0001) from
14·4% (14·2–14·7%) to 42·7% (42·4–42·9%) if the 0·04
threshold was attained. Age and the entry WHO score
were the only other significant risk factors, with the times
increase between the low-risk and high-risk strata ranging
up to 2·14.
Of 1012 participants, 196 (19%) received only
ambulatory care, of whom 194 (99%) had a baseline
COV50 score of less than 0·04; the other 816 (81%)
participants were admitted to hospital and carried
forward in the computation of predicted hospitalisation
costs, on the basis of the Markov-chain transition
probabilities (appendix p 16) and the simulated number
of participants reaching follow-up WHO scores ranging
from 3 to 8 (appendix p 17). The predicted hospitalisation
costs are described in detail in table 4 and summarised
by risk category in the appendix (p 18). In participants at
a low risk (COV50 <0·04), the predicted hospitalisation
costs standardised on the basis of each country’s gross
per capita domestic product to 1000 participants
hospitalised for 1 week in regular care and intermediate
care were greater than intensive care (appendix p 18):
M€4·617 (5–95% percentile interval 4·137–5·103) versus
M€1·591 (0·973–2·170). Among participants at a high
risk (COV50 ≥0·04), the hospitalisation costs showed an
opposite structure, with lower costs in regular plus inter
mediate versus intensive care: M€3·740 (3·289–4·257)
versus M€10·946 (9·596–12·296). Measures of treatment
efficacy, extracted from the literature review and
exemplary trials (appendix p 19), showed reductions in
the number of hospitalisation days or fewer hospital
isation days until recovery. The cost reductions associated
with 1 day less hospitalisation per 1000 participants
(table 4; appendix p 18) were M€0·887 (0·730–1·039) in
participants at a low-risk (COV50 <0·04) and M€2·098
(1·839–2·365) in the high-risk stratum (COV50 ≥0·04).
The 62 participants enrolled in the 2022 substudy
(appendix p 20) were on average aged 64·9 (19·8) years
and included 26 women (42%). These participants had a
high-risk profile, as evidenced by the prevalence of
obesity (n=12 [19%]), hypertension (n=38 [61%]), diabetes
(n=25 [40%]), cancer (n=12 [19%]), chronic obstructive
lung disease (n=7 [11%]), or the use of immuno
suppressants (n=13 [21%]). Moreover, 22 (35%) had a
www.thelancet.com/digital-health Vol 4 October 2022
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history of chronic kidney disease. One patient was
infected by the delta variant and 61 (98%) by the omicron
strain. The number of participants vaccinated was 44
(71%; appendix p 20). Median (5–95th percentile interval)
follow-up was 5 days (1–24), during which
six participants (10%) had a worsening of their baseline
WHO score. Two participants died. The correlation
coefficient of the baseline COV50 score during follow-up
with the baseline WHO score was 0·527 (0·319–0·686)
and for the maximal WHO score, the correlation
coefficient was 0·626 (0·446–0·757); adjusted for the
glomerular filtration rate, these estimates were 0·455
(0·305–0·605) for the baseline WHO score and 0·566
(0·354–0·778) for the maximal WHO score. The ORs
expressing the risk of a worsening WHO score asso
ciated with a 1-SD increment in COV50 were 4·87
(95% CI 1·06–22·4 [p=0·042]) unadjusted; 6·81
(1·25–37·0 [p=0·026]) adjusted for the baseline WHO
score, and 7·14 (1·28–39·8 [p=0·025]) additionally
adjusted for age.

Discussion
COV50 is a novel urinary biomarker, consisting of
50 dysregulated urinary peptides (appendix pp 8–10).
COV50 predicts death and disease progression when
adjusting for clinical risk factors, comorbidities, and the
WHO score at presentation. COV50 analysed as a single
continuously distributed risk factor generated AUCs for
mortality and disease progression substantially greater
than a 10-year age increment or a 1-point increase in the
baseline WHO score (appendix p 14). The opti
mised
COV50 thresholds had 74·4% predictive accuracy
for mortality and 67·4% for disease progression
(appendix p 13). Both COV50 thresholds and COV50 as
continuously distributed variable significantly improved
the AUC (figure). Additional adjustment for the
glomerular filtration rate confirmed the predictive accu
racy of COV50 (appendix p 25).
Specificity, sensitivity, accuracy, and AUC are notable
statistical variables that define the performance of a novel
biomarker. However, when faced with individual
participants, clinicians rarely base treatment strategies on
these metrics, but instead commonly rely on risk-carrying
action thresholds. However, standard COVID-19-related
risk factors, such as sex, age, obesity, and the presence of
comorbidities, are generic in the sense that they predict
worse outcomes for various diseases. The COV50
biomarker was associated with increased mortality and
progression to more severe disease, even with cumulative
adjustment for these risk factors. In analyses from which
participants hospitalised in intensive care units were
excluded (entry WHO score 6), the probability of death or
disease progression increased around 3 times if the
optimised COV50 thresholds were exceeded. Age and the
entry WHO score were other significant risk factors;
however, with no more than an approximately 2-times
increase between the low-risk strata and high-risk strata.
www.thelancet.com/digital-health Vol 4 October 2022

Mortality (108/974 [11%])

Worsening WHO score (259/974 [27%])

Probability of
endpoint

Probability of
endpoint

Times
p value
difference

Times
p value
difference

Sex
Women

13·2% (12·6–13·7%)

··

··

27·4% (27·1–27·6%)

··

Men

15·5% (14·9–15·9%)

1·17

0·15

32·8% (32·5–33·0%)

1·20

··
0·057

Age
<55 years

9·8% (9·1–10·4%)

··

··

23·6% (23·3–23·9%)

··

55–74 years

12·1% (11·5–12·6%)

1·23

··

27·7% (27·4–27·9%)

1·17

≥75 years

21·0% (20·3–21·6%)

2·14

38·9% (38·5–39·2%)

1·64

<0·0001

··
··
0·0007

Entry WHO score
1–3

10·8% (10·3–11·4%)

..

..

35·0% (34·7–35·3%)

··

4–5

17·7% (17·2–18·2%)

1·64

0·0002

25·1% (24·9–25·3%)

0·72

··
0·0019

Obesity
Absent

14·6% (14·3–15·0%)

..

..

30·0% (29·9–30·2%)

··

··

Present

13·9% (13·2–14·5%)

0·95

0·84

30·5% (29·7–30·4%)

1·02

0·99

Comorbidities
Absent

13·4% (12·8–13·9%)

··

··

26·6% (26·3–26·8%)

··

Present

15·1% (14·6–15·7%)

1·13

0·27

33·3% (33·0–33·5%)

1·25

6·2% (5·8–6·6%)

··

··

14·4% (14·2–14·7%)

··

42·7% (42·4–42·9%)

2·97

··
0·029

COV50 score
Less than
threshold

Threshold or 22·3% (21·7–23·0%)
more

3·60

<0·0001

··
<0·0001

974 was the number of patients when patients with an entry WHO score of 6 were excluded. Data presented as
probability, % (95% CI). The probabilities of reaching an endpoint were derived from logistic models, in which all risk
factors were categorised and mutually adjusted. For each risk factor, the lowest risk category was the reference in
2
computing the times difference with higher categories. Obesity was a BMI of at least 30 kg/m . The COV50 threshold
was 0·47 for mortality and 0·04 for worsening WHO score. For both endpoints, the number of events and patients at
risk are given. The significance of each risk factor was derived from the multivariable logistic models.

Table 3: Probability of reaching an endpoint by risk factor

This approach, in which clinical judgement and
experience are key, is likely to become the strategy for
rolling out the COV50 biomarker in the risk stratification
and the care of people infected with COVID-19. A highrisk test outcome should move participants across the
action threshold, allowing the early administration of
effective treatments, either in ambulatory or hospitalised
care. A few exemplary trials selected from an extensive
literature review8 were summarised in the appendix (p 19).
The COV50 test is registered in Germany and available for
clinical application and research purposes throughout
the EU.
The participants enrolled in the CRIT-CoV-U study were
unvaccinated and infected by the contemporary virus
strains in the interval from June 30, 2020, to April 14, 2021.
In the substudy, 61 of 62 participants (98%) had been
infected by the omicron variant and 44 of 62 participants
(71%) had been vaccinated at least once (appendix p 20). In
keeping with the observations in the full CRIT-CoV-U
cohort, the correlation coefficients of COV50 with the
baseline and maximal follow-up WHO scores were
significant, irrespective of the adjustment for glomerular
filtration rate. The unadjusted and adjusted ORs expressing
the risk of a worsening WHO score associated with a 1-SD
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Follow-up WHO score

3–4

Cost reduction associated
with 1 day less in hospital
per 1000 patients
5

6–8

All scores (3–8)

COV50 score (range –3·26 to 3·39; 19–96 years)
Days in regular care

8 (4–13)

Cost of regular care, M€

2·198 (2·094–2·302)

Days in intermediate care

··

Cost of intermediate care, M€

··

14 (8–20)
0·684 (0·608–0·759)
11 (5–17)

14 (6–24)
1·942 (1·723–2·174)
12 (5–23)

1·048 (0·931–1·164)

2·311 (2·050–2·587)

··

··

··

··

··

··

··

··

Days in intensive care

··

··

6 (4–17)

··

··

Cost of intensive care, M€

··

··

2·183 (1·937–2·444)

··

··

Days in all care facilities

··

··

··

Cost of all care, M€

··

··

··

9 (4–15)
10·366 (9·343–11·430)

··
1·481 (1·335–1·633)

COV50 score <0·04 (19–96 years)
Days in regular care

7 (4–12)

Cost of regular care, M€

2·732 (2·574–2·897)

12 (6–16)
0·897 (0·744–1·050)

20 (10–29)

Days in intermediate care

··

8 (5–13)

Cost of intermediate care, M€

··

0·988 (0·819–1·156)

0·592 (0·337–0·807)

0·494 (0·315–0·674)
38 (18–58)

··

··

··

··

··

··

··

··
··

Days in intensive care

··

··

6 (4–11)

··

Cost of intensive care, M€

··

··

0·505 (0·321–0·689)

··

··

Days in all care facilities

··

··

··

8 (4–13)

··

Cost of all care, M€

··

··

··

6·208 (5·110–7·273)

0·887 (0·730–1·039)

COV50 score ≥0·04, (19–96 years)
Days in regular care
Cost of regular care, M€

10 (5–14)
1·696 (1·548–1·860)

Days in intermediate care

··

Cost of intermediate care, M€

··

16 (10–20)
0·855 (0·723–1·003)
14 (8–21)

12 (5–23)
3·338 (2·926–3·749)
12 (5–20)

1·189 (1·005–1·394)

3·911 (3·429–4·394)

··

··

··

··

··

··

··

··
··

Days in intensive care

··

··

6 (4–18)

··

Cost of intensive care, M€

··

··

3·697 (3·241–4·153)

··

Days in all care facilities

··

··

··

11 (5–17)

Cost of all care, M€

··

··

··

14·686 (12·872–16·553)

··
··
2·098 (1·839–2·365)

COV50 score ≥0·04, <65 years
Days in regular care

7 (4–16)

Cost of regular care, M€

1·481 (1·257–1·704)

Days in intermediate care

··

17 (14–20)
1·700 (1·373–1·962)
12 (6–15)

30 (24–36)
3·235 (2·654–3·898)
15 (6–19)

··

··

··

··

··

··

Cost of intermediate care, M€

··

2·001 (1·616–2·309)

3·415 (2·802–4·116)

··

··

Days in intensive care

··

··

5 (4–14)

··

··

··

··

Cost of intensive care, M€

··

··

3·200 (2·626–3·856)

Days in all care facilities

··

··

··

11 (5–17)

Cost of all care, M€

··

··

··

15·032 (12·328–17·845)

··
2·147 (1·761–2·549)

COV50 score ≥0·04, ≥65 years
Days in regular care
Cost of regular care, M€

10 (5–14)
1·785 (1·581–1·977)

12 (10–20)
0·139 (0·109–0·169)
16 (8–24)

11 (4–26)
1·194 (1·027–1·362)

Days in intermediate care

··

Cost of intermediate care, M€

··

0·881 (0·688–1·074)

12 (4–25)

Days in intensive care

··

··

Cost of intensive care, M€

··

··

3·972 (3·415–4·529)

4·130 (3·551–4·709)
12 (6–20)

··

··

··

··

··

··

··

··

··

··

··

··

Days in all care facilities

··

··

··

11 (5–17)

Cost of all care, M€

··

··

··

12·101 (10·371–13·820)

··
1·729 (1·482–1·974)

Data shown as the median number of days (IQR) as observed in the CRIT-Cov-U cohort; and hospitalisation costs per 1000 patients hospitalised for 1 week per care facility (median and 5–95% percentile interval)
were extrapolated from the distributions of patients (expected by the Markov chain simulation) reaching follow-up WHO scores of 3–4, 5, and 6–8 and the care facility corresponding with disease severity (ie,
regular care for score 3–4, intermediate care for score 5, and intensive care for score 6–8). Cost estimates in intermediate and intensive care facilities also include the costs of lower care facilities to which patients
were admitted before or after they reached their maximal WHO score during follow-up. M€=million Euro.

Table 4: Simulated hospitalisation costs by baseline COV50 score, age class, and the hospital facility at entry
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increment in COV50 (6 events [10%]) were significant.
Nevertheless, these ORs are only presented for information
purposes, given that only six participants of 62 participants
had worsening WHO scores, resulting in wide CIs.
Urine specimens contain more than 20 000 peptides, of
which approximately 5000 are typically detectable in a
single urine sample. These peptides provide a molecular
signature of progressing SARS-CoV-2 infection inde
pendent of the virus strain. A comprehensive multilevel
proteomic study13 profiled the interactome of SARS-CoV-2
and its influence on transcriptome, proteome,
ubiquitinome, and phosphoproteome of a lung-derived
human cell line. This study revealed that SARS-CoV-2
infection dysregulates the transcription of the growth
factor β pathway, known for its involvement in tissue
fibrosis and epidermal growth factor receptor-mediated
signalling, which downstream modulates cell survival
and motility and the innate immune responses. The
activation of the transcription growth factor β pathway is
in keeping with the most prominent characteristic of the
COV50 UPP (appendix pp 8–10), which is the shift in
collagen fragments, in particular collagen α1.2 On
infection, the reactive inflammatory cascade activates
fibroblasts,14 leading to excessive extracellular matrix
deposition in response to injury. The COV50 UPP
signature also points to enhanced α1-antitrypsin degrad
ation in line with reports showing that α1-antitrypsin
deficiency is associated with life-threatening COVID-19.15
Another hallmark of the COV50 UPP is the reduction in
urinary peptides derived from CD99.16 This observation
reflects the loss of endothelial integrity, interference with
the transendothelial migration of monocytes, neutro
phils, and T cells,16 and damage of the endothelial tight
junctions. The resulting exposure of collagen to the
circulating blood triggers the thrombotic complications
specific for COVID-19.17 As is also observed in chronic
obstructive lung disease,18 with increasing COVID-19
severity, the UPP reveals downregulation of the polymeric
immunoglobulin receptor,16 which is highly expressed in
the trachea and the lung and mediates IgA transcytosis.18
Thus, the urinary peptide fragments included in the
multidimensional COV50 biomarker are compatible
with the established molecular pathogenic mechanisms
activated by SARS-CoV-2 infection. In addition to these
molecular mechanisms, reduced disease tolerance (as
associated with chronological ageing), accelerated
biological ageing,19 comorbidities, and frailty drive
disease progression.20 Of note, the key results shown in
the figure were adjusted for sex, age, BMI, and the WHO
stage at enrolment. Furthermore, socioeconomic
deprivation, low educational attainment, insufficient
disease awareness, misinformation, and inadequate
access to health care or vaccination are non-biomolecular
factors underlying adverse health outcomes in people
with COVID-19.21
Cost-effectiveness balances health-care costs against
non-monetary units, such as quality-adjusted life-years
www.thelancet.com/digital-health Vol 4 October 2022

(QALYs).22 The QALY-based value proposition is well
established in the UK, Sweden, Belgium, the Netherlands,
Luxembourg, and some eastern European countries, but
health-care insurers in Germany and France prefer
assessing changes in clinical outcomes instead.22 CRITCoV-U was not designed to address health-economic
issues. The administration of quality-of-life questionnaires,
the instruments to turn QALY’s into metrics, was
impossible in an emergency care setting. Ethics approvals
allowing access to claims databases were not requested.
However, the simulations in the current Article
(table 4; appendix p 18) provide some information on
the balance between the costs of administering the
COV50 test (M€0·850 per 1000 participants) against
potential health-care savings associated with earlier
intervention; for instance on account of the reduction in
the number of hospitalisation days, reported to be
5–10 days in three trials.23–25 Because a high UPP risk
profile justifies an earlier intervention rather than later
treatment guided by clinical deterioration, presumably
applying the test will not affect drug costs. One possible
limitation of the Markov chain simulation is that the
WHO scores at presentation of the participants in CRITCoV-U were used as the initial distribution vector, so the
medians of the simulated patient distributions, as
presented in the appendix (p 17), closely reflect the
baseline distribution vector. However, the main objective
of running the Markov chain analysis was to generate
uncertainty intervals as captured by the 5th and
95th percentiles of the simulated number of participants
with possible outcomes.
Among the strong points of our study is the high
consistency in the discriminatory performance of COV50
among participants recruited both initially and later
(table 2; appendix pp 13–15), which shows a high degree
of cohesion in the results within the CRIT-CoV-U cohort.
The calibration of the UPP profile (appendix p 3)
accounts for interindividual differences in renal function
and urinary flow. Furthermore, additional adjustment for
the glomerular filtration rate in participants admitted to
hospital strengthened the main analysis in the full cohort
and showed that the calibration had met its objective
(appendix pp 15, 25). Nevertheless, the current results
should also be interpreted within the context of obvious
limitations. First, CRIT-CoV-U is an observational cohort
study. Randomised clinical trials are the optimal strategy
for applying treatments guided by COV50 risk profiling.
Second, as outlined above, future research should
address the health-economic implications of the timing
and choice of therapeutic interventions in participants
with a low-risk COV50 score versus a high-risk COV50
score. Third, CRIT-CoV-U enrolled adults, who were
predominantly white Europeans. How ethnicity might
affect the UPP is currently under investigation in the
Urinary Proteomics Combined with Home Blood
Pressure Telemonitoring for Health Care Reform trial
(NCT04299529).26 Along similar lines, the recruitment of
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participants into the present study involved 19 centres in
eight countries and was driven by the temporal and
geographical spread of the successive waves of the
pandemic. Therefore, it is difficult to assess to what
extent the study participants were representative of the
wider population, in which the COV50 test might be
used in clinical practice. Fourth, one limitation of the
capillary electrophoresis combined with mass
spectrometry approach is the application of ultrafiltration
with the threshold set at 20 kDa, so that larger proteins
escape analysis. Finally, although UPP risk profiling
provides insight on the ideal timing of intervention,
vaccination is by far the primordial strategy in addressing
the COVID-19 pandemic, although vaccination alone
cannot be sufficient to restore population health to the
pre-COVID-19 era.3
In conclusion, to our knowledge COV50 is a novel
biomarker predictive of death and disease progression in
adults with COVID-19. Independent of clinical risk
markers, the oper
ational COV50 thresholds have a
discriminatory accuracy of approximately 70%, even in
participants with mild disease. A high-risk COV50 test
administered within 4 days of a positive PCR test justifies
earlier treatment in participants with mild-to-moderate
disease (WHO scores 1–4), in whom clinical risk factors
often leave the prognosis uncertain. Another potential
application of COV50 is in the selection of participants to
be enrolled in randomised clinical trials of novel
COVID-19 therapies, in which risk is an issue in the
choice between ambulatory versus hospitalised care or in
which a treatment method is being tested.
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